2,5-Dimethylpyrrole is a heterocyclic organic compound with the formula C6H9N. It is a colorless liquid with a pungent odor. It is a common building block for the synthesis of pharmaceuticals, polymers, and other organic compounds. 2,5-Dimethylpyrrole is used in the synthesis of the drug, Aprepitant, which is used to treat nausea and vomiting. It is also used in the synthesis of the polymer, polyvinylpyrrolidone, which is used in a variety of applications, including hair care products, pharmaceutical formulations, and food additives. 2,5-Dimethylpyrrole is also used in the synthesis of other organic compounds, such as pyrroles, indoles, and porphyrins. 2,5-Dimethylpyrrole is studied for its potential medicinal and industrial applications.'
2,5-dimethylpyrrole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 12265 |
| CHEMBL ID | 3901947 |
| CHEBI ID | 185789 |
| MeSH ID | M0184493 |
| Synonym |
|---|
| nsc 4507 |
| einecs 210-913-8 |
| 2,5-dimethylazole |
| unii-mz3oyf5521 |
| mz3oyf5521 , |
| ec 210-913-8 |
| 2,5-dimethyl-1h-pyrrol |
| nsc-4507 |
| pyrrole,5-dimethyl- |
| 2,5-dimethylpyrrole |
| 1h-pyrrole,5-dimethyl- |
| 625-84-3 |
| nsc4507 |
| pyrrole, 2,5-dimethyl- |
| 1h-pyrrole, 2,5-dimethyl- |
| inchi=1/c6h9n/c1-5-3-4-6(2)7-5/h3-4,7h,1-2h |
| 2,5-dimethyl-1h-pyrrole |
| pyrrole,2,5-dimethyl |
| 2,5-dimethylpyrrole, 98% |
| D0260 |
| CHEBI:185789 |
| AKOS002664627 |
| A833863 |
| NCGC00188231-01 |
| FT-0610478 |
| 2,5-dimethylpyrrole [fcc] |
| 2,5-dimethyl pyrrole |
| 2,5-dimethyl-pyrrole |
| J-650358 |
| W-104990 |
| DTXSID40211552 |
| bdbm181149 |
| us9138423, 2,5-dimethyl-1h-pyrrole |
| mfcd00005223 |
| 2, 5-dimethylpyrrole |
| pyrrole, 2,5-dimethyl- (8ci) |
| CS-W011343 |
| CHEMBL3901947 |
| F1918-0031 |
| BCP18596 |
| Q27284301 |
| 2,5-1h-dimethylpyrrole |
| SB63881 |
| O10615 |
| EN300-49164 |
| 2, 5-dimethyl-1h-pyrrole |
| Class | Description |
|---|---|
| pyrroles | An azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Porphobilinogen deaminase | Homo sapiens (human) | Ki | 3.0000 | 3.0000 | 3.0000 | 3.0000 | AID1618722 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protoporphyrinogen IX biosynthetic process | Porphobilinogen deaminase | Homo sapiens (human) |
| heme biosynthetic process | Porphobilinogen deaminase | Homo sapiens (human) |
| heme A biosynthetic process | Porphobilinogen deaminase | Homo sapiens (human) |
| heme B biosynthetic process | Porphobilinogen deaminase | Homo sapiens (human) |
| heme O biosynthetic process | Porphobilinogen deaminase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hydroxymethylbilane synthase activity | Porphobilinogen deaminase | Homo sapiens (human) |
| protein binding | Porphobilinogen deaminase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Porphobilinogen deaminase | Homo sapiens (human) |
| cytoplasm | Porphobilinogen deaminase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.95) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||